A novel pacemaker designed to mimic a patient’s organic breath increased blood flow to the heart in a study of individuals with heart failure, according to research published in the journal Thorax.

Patients with heart failure and reduced ejection fraction are well served by treatment with the glucose-lowering drug dapagliflozin, as it warded off death and hospitalization while also improving quality of life when added to standard care regimens in a major trial.

Apple has opted to remove all vaping-related apps from its App Store in the midst of an e-cigarette epidemic that’s fueled more than 2,000 cases of vaping-related lung injury and at least 42 fatalities.

Results of the late-breaking COLCOT trial, which explored the efficacy of low-dose colchicine in reducing CV risk in heart attack patients, were a highlight of the American Heart Association’s 2019 Scientific Sessions this month in Philadelphia.

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted unanimously Nov. 14 to recommend an expanded indication for icosapent ethyl, a purified omega-3 product designed to help heart patients keep their lipid levels in check.

Research that will be presented at the American Heart Association’s Resuscitation Science Symposium in Philadelphia this month suggests the National Institutes of Health invests far less money in cardiac arrest research than in research for other conditions, including diabetes, drug-use disorders and ischemic heart disease.

Young people who use cannabis—especially if they’re frequent users—could face an up to threefold increased risk of stroke compared to their peers, researchers have found.